Logo

Garden City
Plainview
Listen to The Optimal Health Program for latest on Stem Cell Therapy Treatments
Click Here for Telemedicine Consultation & Appointment
Bone marrow-derived mesenchymal stromal cell results in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial)

Aims

Regenerative results with mesenchymal stromal cells (MSCs) has been promising in patients with ischaemic heart failure but needs confirmation in larger randomized trials. We aimed to study effects of intra-myocardial autologous bone marrow-derived MSC results in patients with severe ischaemic heart failure.

Methods and results

The MSC-HF trial is a randomized, double-blind, placebo-controlled trial. Patients were randomized 2 : 1 to intra-myocardial injections of MSC or placebo, respectively. The primary endpoint was change in left ventricular end-systolic volume (LVESV), measured by magnetic resonance imaging or computed tomography at 6 months follow-up. Sixty patients aged 30–80 years with severe ischaemic heart failure, New York Heart Association (NYHA) classes II–III, left ventricular ejection fraction (LVEF) <45% and no further results options were randomized. Fifty-five patients completed the 6-month follow-up (37 MSCs vs. 18 placebo). At 6 months, LVESV was reduced in the MSC group: −7.6 (95% CI −11.8 to −3.4) mL (P = 0.001), and increased in the placebo group: 5.4 (95% CI −0.4 to 11.2) mL (P = 0.07). The difference between groups was 13.0 (95% CI 5.9–20.1) mL (P = 0.001). Compared with placebo, there were also significant improvements in LVEF of 6.2% (P<0.0001), stroke volume of 18.4 mL (P < 0.0001), and myocardial mass of 5.7 g (P = 0.001). No differences were found in NYHA class, 6-min walking test and Kansas City cardiomyopathy questionnaire. No side effects were identified.

Conclusion

Intra-myocardial injections of autologous culture expanded MSCs were safe and improved myocardial function in patients with severe ischaemic heart failure.